Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) is expected to announce its Q1 2026 resultson Tuesday, August 11th. Analysts expect the company to post earnings of ($1.54) per share and revenue of $0.10 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:00 PM ET.

Lyra Therapeutics Stock Down 15.0%

LYRA opened at $0.34 on Friday. Lyra Therapeutics has a twelve month low of $0.00 and a twelve month high of $8.75. The company’s 50-day moving average price is $0.58 and its two-hundred day moving average price is $0.88. The stock has a market cap of $603,500.00, a price-to-earnings ratio of -0.01 and a beta of 0.72.

Hedge Funds Weigh In On Lyra Therapeutics

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its position in Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after buying an additional 7,190 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Lyra Therapeutics in the third quarter valued at $128,000. Finally, DRW Securities LLC purchased a new position in shares of Lyra Therapeutics during the 4th quarter valued at $52,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Lyra Therapeutics Company Profile

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).